The increasing availability of biosimilar medicines in Middle Eastern regions may provide an opportunity to increase the number\nof rheumatology patients who have access to traditionally more expensive biologicmedicines. However, as well as a lack of realworld\ndata on the use of biosimilar medicines in practice, the availability of intended copies in the region may undermine\nphysician confidence in prescribing legitimate biosimilar medicines. There is a need for regional recommendations for healthcare\nprofessionals to ensure that biosimilar drugs can be used safely. Therefore, a literature search was performed with the aim of\nproviding important recommendations for the regulation and use of biosimilar medicines in the Middle East from key opinion\nleaders in rheumatology fromthe region. These recommendations focus on improving the availability of relevant real-world data,\nensuring that physicians are aware of the difference between intended copies and true biosimilars and ensuring that physicians are\nresponsible for making any prescribing and switching decisions.
Loading....